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Objectives. The purpose of this study was to examine the impact
of sulfonylurea drug use on outcome in diabetic patients under-
going direct coronary angioplasty for acute myocardial infarction.
Background. Sulfonylurea drugs impair ischemic precondition-
ing. Whether sulfonylurea drugs affect outcome adversely in
diabetic patients undergoing direct angioplasty for acute myocar-
dial infarction is unknown.
Methods. Clinical outcomes after direct balloon angioplasty for
acute myocardial infarction were evaluated in 67 diabetic patients
taking oral sulfonylurea drugs and 118 diabetic patients not
taking these drugs.
Results. Hospital mortality was significantly higher among
diabetics treated with sulfonylurea drugs at the time of myocar-
dial infarction (24% vs. 11%). Univariate analysis identified
sulfonylurea drug, age, ventricular function, ejection fraction less
than 40%, prior bypass surgery and congestive heart failure as
correlates of increased in-hospital mortality. Logistic regression
found sulfonylurea drug use (odds ratio 2.77, p 5 0.017) to be
independently associated with early mortality. Congestive heart
failure, but not sulfonylurea drug use, was associated with an
increased incidence of in-hospital ventricular arrhythmias. Con-
gestive heart failure, prior bypass surgery and female gender, but
not sulfonylurea drug use, were associated with late adverse
events.
Conclusions. Sulfonylurea drug use is associated with an
increased risk of in-hospital mortality among diabetic patients
undergoing coronary angioplasty for acute myocardial infarction.
This early risk is not explained by an increase in ventricular
arrhythmias, but may reflect deleterious effects of sulfonylurea
drugs on myocardial tolerance for ischemia and reperfusion. For
surviving patients sulfonylurea drug use is not associated with an
increased risk of serious late adverse events.
(J Am Coll Cardiol 1999;33:119–24)
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Patients with diabetes mellitus account for a large proportion
of patients admitted with acute myocardial infarction (MI) and
as a whole have a poorer prognosis when compared to
nondiabetic patients (1–3). Moreover, diabetic patients with
ischemic heart disease have a substantially worse outcome
following coronary interventional procedures despite similar
rates of procedural success when compared to patients without
diabetes (4,5). The basis for these differences in outcome
remains unresolved.
Among possible contributing factors, use of sulfonylurea
hypoglycemic agents has been reported to increase cardiovas-
cular mortality in patients with non–insulin dependent (type
II) diabetes mellitus (6,7). The mechanism of action and the
controversy surrounding the clinical use of sulfonylurea drugs
has recently been reviewed in detail (8). Sulfonylureas, while
promoting release of insulin (9–11) through blockade of
metabolism regulated adenosine triphospate–sensitive potas-
sium channel (KATP) channels present in pancreatic b-cell
membranes (12,13), also block KATP channels present in
cardiac cells and coronary vasculature (14–17). This action
impairs ischemic preconditioning (18–20) and prevents coro-
nary vasodilation in response to ischemia (21–23). Since isch-
emic preconditioning and coronary vasodilation act to protect
the heart against ischemic insults (24), sulfonylurea drug action
within the myocardium may increase its vulnerability to isch-
emia (25). Furthermore, sulfonylureas impair ischemic precon-
ditioning during coronary angioplasty, leading to increased
clinical manifestations of ischemia (26). However, there have
been no clinical reports of increased mortality in patients with
ischemic heart disease treated with glibenclamide, a sulfonyl-
urea with known high affinity for myocardial KATP channels
(15,16), and no data are available that address specifically
outcomes in diabetic patients with MI undergoing direct
coronary angioplasty while taking sulfonylurea drugs.
To address this, we examined mortality and other adverse
events among diabetic patients undergoing direct balloon
angioplasty for acute MI, and assessed the effects of oral
sulfonylurea hypoglycemic drug use on clinical outcome.
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Methods
Patient population. Patients with preexisting diabetes mel-
litus undergoing direct coronary angioplasty for treatment of
acute MI between January 1985 and December 1994 were
identified retrospectively from the Mayo Clinic coronary inter-
vention database. This cutoff date was selected to assure
against inclusion of patients using metformin, a nonsulfonylu-
rea oral hypoglycemic agent available commercially in North
America after December 29, 1994. Initial data for each patient
were entered into the database prospectively, and follow-up
data were obtained through review of medical records for all
hospital and outpatient visits at Mayo Clinic and affiliated
hospitals, and from a standardized questionnaire completed at
6 and 12 months following intervention, and annually thereaf-
ter. Adverse events were corroborated through review of
medical records and death notices. In accordance with Minne-
sota law, only patients who consented to the use of their
clinical records for research purposes were included in this
study; the number of eligible patients not included for this
reason was zero. This study was approved by the Mayo Clinic
Institutional Review Board.
Medical treatment. Patients were divided into two groups
on the basis of their use of diabetic medications. Group 1
consisted of diabetic patients with acute MI taking an oral
sulfonylurea drug at the time of angioplasty, and group 2
consisted of diabetic patients with acute MI not taking a
sulfonylurea drug. All patients were treated with conventional
doses of heparin, aspirin, beta-adrenergic blocking drugs and
nitroglycerin according to established protocols for the care of
patients with acute MI.
Coronary angiography and revascularization. Coronary
angiography was performed in patients immediately upon
presentation with acute MI. All patients were treated with
direct balloon angioplasty employing standard technique; non-
balloon coronary intervention devices (atherectomy devices,
lasers or stents) were not evaluated in this study. Multivessel
disease was considered present when angiographic narrowing
of $70% involving at least one major coronary artery was
accompanied by a narrowing of $50% in at least one other
artery. Procedural success was defined as improvement of
.40% luminal diameter in all lesions treated. Abrupt closure
was defined as reduction of anterograde coronary blood flow to
Thrombolysis in Myocardial Infarction trial grade 0–1 after
angioplasty. Circulatory shock was defined as systolic blood
pressure ,90 mm Hg or cardiac output ,2.5 liters/min.
Clinical success was defined as procedural success without
death, Q wave MI or urgent coronary artery bypass graft
surgery (CABG).
End points. In-hospital adverse events assessed included
death, serious ventricular arrhythmias (fibrillation or sustained
tachycardia), procedural success and complications, recurrent
Q wave MI, need for CABG or repeat angioplasty procedures
and postprocedural renal insufficiency (defined as an elevation
of creatinine to .2.5 mg/dl). Late events assessed included
death, postdischarge MI (Q wave and non–Q wave), need for
additional angioplasty procedures or CABG and presence of
recurrent severe angina. Correlates of in-hospital mortality,
in-hospital ventricular arrhythmias, late death and a combined
late end point of death, repeat MI, recurrent severe angina,
CABG or repeat target vessel angioplasty were sought.
Statistical analysis. Demographic characteristics and in-
hospital adverse events in the two patient groups were com-
pared using chi-square and student t test as appropriate.
Stepwise logistic regression was used to model correlates of
in-hospital adverse events. Variables included in the model
were age, presence of congestive heart failure, left ventricular
ejection fraction (LVEF), LVEF ,40% (as a separate discrete
variable), family history of atherosclerotic heart disease, gen-
der, glycosylated hemoglobin (HgbA1C), HgbA1C .8.5% (as
a separate discrete variable), hypercholesterolemia (defined as
total serum cholesterol $250 mg/dl), hypertension (defined as
diastolic blood pressure .90 mm Hg and/or systolic blood
pressure .140 mm Hg), multivessel coronary disease, prior
CABG and sulfonylurea drug use. Cox proportional hazard
modeling was used to develop models for late mortality, MI,
severe angina and a composite of these three end points.
Results
Baseline characteristics. One hundred and eighty-eight
diabetic patients were identified who presented with acute MI
and who were treated with direct balloon angioplasty during
the study period. The use of sulfonylurea agents was uncertain
in three patients, so they were excluded from analysis. Of the
remainder, 67 were taking oral sulfonylurea hypoglycemic
agents at the time of treatment (group 1), and 118 were not
(group 2); 70 group 2 patients were using insulin, and 38 were
controlled without either insulin or oral hypoglycemic agents.
Clinical and angiographic characteristics of both groups are
summarized in Table 1. Patients in group 1 were significantly
older, and had a significantly lower mean LVEF when com-
pared with group 2 (Table 1). Other factors known to affect
mortality, such as extent of disease, incidence of congestive
heart failure and infarct location, were similar in the two
groups.
Procedural characteristics and success. In group 1, proce-
dural success was achieved in 50 (74.6%) patients, which
included 73 (85.9%) lesions. In group 2, procedural success
was achieved in 95 (80.5%) patients, and 122 (84.1%) lesions.
Overall rates of procedural success were not significantly
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 95% confidence interval
HbgA1C 5 glycosylated hemoglobin
KATP 5 adenosine triphosphate–sensitive
potassium channel
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
OR 5 odds ratio
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different between the two groups. Although the incidence of
circulatory shock was not significantly different, patients in
group 1 required insertion of an intra-aortic balloon pump
more frequently than patients in group 2 (p 5 0.046) (Table 2).
In-hospital events. Despite similar rates of procedural
success, in-hospital mortality was higher in patients from group
1 than group 2 (24% vs. 11%, p 5 0.02). All early deaths were
caused primarily by pump dysfunction with cardiogenic shock
except for five arrhythmic deaths (two bradyarrhythmic events,
three ventricular tachycardic or fibrillation events). Two pa-
tients died following emergency CABG. Logistic regression
analysis found use of oral sulfonylurea agents to be associated
with an increased risk of death (Table 3). Other variables
associated independently with an increased risk of early mor-
tality included LVEF, LVEF ,40%, prior CABG, age and
congestive heart failure. Multivariate analysis found oral sul-
fonylurea drug use to be independently associated with in-
creased early mortality (Fig. 1).
Ventricular tachycardia or fibrillation occurred in 27% of
group 1 and 22% of group 2 patients (p 5 NS). The presence
of congestive heart failure (odds ratio [OR] 5 2.77, 95%
confidence interval [CI] 5 1.2 to 6.60, p 5 0.03) and male
gender (OR 5 2.53, CI 5 1.04 to 6.14, p 5 0.04), but not
sulfonylurea drug use, were associated multivariately with an
increased frequency of in-hospital ventricular fibrillation.
Rates of other adverse events, including recurrent MI and
the need for additional revascularization procedures, were
similar in the two groups.
Late events. Follow-up was available for all hospital survi-
vors. Mean follow-up was 3.8 6 2.3 years (range: 0.1 to 9.9
years) for group 1, and 3.6 6 2.4 years (range: ,0.1 to 9.1
years) for group 2. Although repeat coronary angioplasty
procedures were performed more frequently for group 2
patients during the follow-up period (17.8% vs. 46.7% within 5
years after treatment, p 5 0.05), no difference in the frequency
of subsequent MI (19.9% vs. 23.1% at 5 years, p 5 NS), need
for CABG (23.3% vs. 31.7% at 5 years; p 5 NS) or late
mortality was found between the two groups. Only congestive
heart failure (relative risk 5 3.10, CI 5 1.47 to 6.51, p 5 0.003)
was associated with an increased relative risk of death during
the follow-up period.
Multivariate modeling identified only prior CABG to be
associated with the combined end point of late death, MI,
severe angina, CABG or repeat target vessel angioplasty.
Discussion
This study finds that the risk of death for diabetic patients
undergoing balloon angioplasty for acute MI is 2.77 times
higher if they are using an oral sulfonylurea hypoglycemic
agent at the time of treatment. The impact of sulfonylurea
drug use on early mortality was similar to the impact of
reduced LVEF or overt clinical heart failure. Thus, use of
sulfonylurea drugs may represent an additional risk factor in
patients undergoing coronary interventional procedures in the
presence of MI.
Sulfonylureas and mortality. Prior indication that sulfonyl-
urea drug use may have adverse consequences in diabetic
patients with cardiac disease came from epidemiological stud-
ies that demonstrated increased cardiovascular mortality
among patients taking these agents (7). Although this obser-
vation generated much controversy, a similar conclusion was
reached in a subsequent study that found increased mortality
following MI in diabetic patients treated with sulfonylureas
when compared to diabetic patients treated with insulin (6).
The present study is consistent with these observations, and
suggests that sulfonylurea drug use may increase mortality
specifically among diabetic patients with MI undergoing acute
revascularization therapy through coronary angioplasty. This
Table 1. Patient Characteristics
Clinical Characteristic Group 1 (n 5 67) Group 2 (n 5 118) p Value
Men, n (%) 40 (59.7%) 73 (61.9%) NS
Mean age (yr 6 SD) 68.4 6 10.5 63.2 6 11.7 0.003
Current smoker, n (%) 7 (10.4%) 20 (16.9%) NS
Hypertension, n (%) 41 (61.2%) 80 (67.8%) NS
Hypercholesterolemia, n (%) 20 (29.9%) 37 (31.4%) NS
Prior CABG, n (%) 6 (9%) 13 (11%) NS
Mean LVEF, % 6 SD 47.3 6 14.7 (n 5 29) 55.3 6 14 (n 5 51) 0.019
Congestive heart failure, n (%) 14 (20.9%) 24 (20.3%) NS
Multivessel disease, n (%) 39 (61.2%) 70 (6.7%) NS
Anterior MI, n (%) 31 (46%) 50 (42%) NS
gb 5 coronary artery bypass graft surgery; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
Table 2. Procedural Success and Complications of Angioplasty
Parameter Group 1 Group 2 p Value
Successful procedure, n (%) 50 (74.6%) 95 (80.5%) NS
Coronary segments treated, n 85 145 —
Successful lesions, n (%) 73 (85.9%) 122 (84.1%) NS
Complete revascularization, n (%) 30 (44.8%) 43 (36.4%) NS
Abrupt closure, n (%) 10 (14.9%) 9 (7.6%) NS
Shock, n (%) 4 (6%) 7 (5.9%) NS
Intra-aortic balloon pump, n (%) 5 (7.5%) 2 (1.7%) 0.046
Postprocedure renal failure, n (%) 4 (6%) 0 0.007
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increased mortality could not be explained on the basis of
differences in age, ventricular function, hyperglycemic control
or procedural success between diabetic patients taking and not
taking these drugs.
We did not find sulfonylurea drug use to be associated with
an increased incidence of ventricular arrhythmias, suggesting
that the observed increased mortality was not due to an
increase in electrical instability in these patients. Thus, use of
sulfonylurea drugs per se appears to be associated with worse
early outcome in this patient population, but the mechanisms
whereby sulfonylurea drugs may increase mortality have not
been defined.
Potential explanations for increased mortality with sulfo-
nylurea drugs. Experimentally, sulfonylureas increase infarct
size and accelerate the death of hypoxic cardiomyocytes
through blockade of KATP channels that mediate ischemic
preconditioning in myocardium (8,27,28). Increased vulnera-
bility of myocardium to ischemic insult in the presence of
sulfonylurea drugs may have contributed to the increased
mortality observed in this group of diabetic patients. Indeed, it
has been demonstrated in isolated human myocardium (18)
and in patients undergoing balloon angioplasty (26) that
sulfonylurea drug treatment abolishes the cardioprotective
efficacy of ischemic preconditioning. Although the extent of
cell damage was not measured in the present study, increased
ischemic myocardial injury should result in greater impairment
of contractile function, which is an important known determi-
nant of survival after acute MI (29,30). In this regard, our
observations that the mean left ventricular ejection fraction
was lower and requirement of intra-aortic balloon pump
support was greater among patients taking sulfonylurea drugs
are of interest.
Other mechanisms by which sulfonylureas may increase
mortality in patients with MI include inhibition of the endog-
enous fibrinolytic system (31). This could be effected through
enhanced production of proinsulin, which is known to stimu-
late endothelial production of plasminogen activator
inhibitor-1 (32–34). Elevated serum levels and activity of this
inhibitor have been documented in animals and diabetic
patients given sulfonylurea drugs (32,35–37), and resistance to
tissue-type plasminogen activator has also been observed
(38,39). This effect could also be mediated by lipoprotein(a)
levels, which have been observed to correlate well with plas-
minogen activator inhibitor-1 activity and antigen levels
(35,40) among diabetic patients using sulfonylurea drugs.
When metformin, an antidiabetic biguanide compound, was
substituted for sulfonylurea drugs in non–insulin dependent
diabetic patients the abnormalities in plasminogen activator
inhibitor-1 behavior improved without changes in lipopro-
tein(a) levels, suggesting a direct effect from sulfonylurea
drugs, although the degree of individual improvement was
related to the baseline lipoprotein(a) levels (40). These are
important considerations, since refractory thrombosis is a
recognized cause of failed angioplasty for acute MI (41–43).
Figure 1. Multivariate correlates of in-hospital mortality (odds ratios
and 95% confidence intervals).
Table 3. Logistic Model for In-Hospital Death
Variable p Value OR
95% Confidence Intervals
Lower Upper
Oral sulfonylurea use 0.024 2.534 1.133 5.666
HgbA1C 0.628 0.954 0.789 1.154
HgbA1C .8.5% 0.655 0.780 0.262 2.322
LVEF 0.019 0.940 0.895 0.990
LVEF ,40% 0.009 7.467 1.669 33.407
Congestive heart failure 0.059 2.305 0.970 5.477
Gender 0.113 2.203 0.847 4.859
Prior CABG 0.011 3.818 1.357 10.743
Hypertension 0.681 0.842 0.371 1.912
Hypercholesterolemia 0.641 1.221 0.528 2.823
Emergency procedure 0.380 1.439 0.638 3.240
Age 0.016 1.050 1.009 1.093
Age $75 yr 0.024 2.676 1.142 6.272
Family history of coronary disease 0.068 0.150 0.020 1.147
Multivessel disease 0.224 2.186 0.620 7.700
Anterior MI 0.060 0.433 0.181 1.037
HgbA1C 5 glycosylated hemoglobin; OR 5 odds ratio; other abbreviations as in Table 1.
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However, we observed no differences in the extent of refrac-
tory thrombosis but rather found similar overall procedural
success rates during coronary intervention, suggesting that the
principal mechanism by which sulfonylurea drugs increased
mortality was not impaired endogenous fibrinolysis.
Sulfonylureas and late events. The finding that sulfonyl-
urea drug use was not associated with an increased incidence
of late events (other than the need for repeat balloon angio-
plasty) is consistent with our earlier observations (44). Un-
selected diabetic patients with MI treated with a variety of
management strategies had similar late outcomes (2.7 6 2.3
years) whether taking sulfonylurea drugs at the time of MI or
not. This suggests either that the early mortality among
diabetic patients using sulfonylurea drugs precluded the op-
portunity to observe late events in this group, or that the
principal deleterious effects of sulfonylurea drug use are
observed predominantly in the period of acute myocardial
ischemia; the latter is consistent with previous studies, which
indicate that the time of exposure to the drug and the state of
the myocardium are important determinants of the conse-
quences of sulfonylurea drug use (18,27,45,56).
Study limitations. The limitations of this study include the
retrospective study design, and the limited number of patients
with diabetes who underwent direct balloon angioplasty during
the 10-year study period. Postulates regarding the potential
role of KATP channels and other possible mediators of in-
creased mortality are consistent with, but not supported di-
rectly by, the data presented. Patients not receiving sulfonyl-
urea drugs were not analyzed further, so no conclusions may be
made regarding the potential effects of other antidiabetic
treatment strategies in the setting of acute MI (including the
possible impact of oral biguanide therapy). Since only balloon
angioplasty was studied, the impact of other catheter-based
therapies, such as coronary stents, remains unknown.
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